| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d22b649c54d79d7c1eabf23085b14a3e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6037
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2014-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d13d2f9a27cea07fd1b39d1313d990c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1b7c94d7aba0e5817d6da830ad9f54b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e998765461840c59a581a9e6cb4ada7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a0057ab81cdc70d3c10b01aed74bd5a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b47a192728da6bada3430115d4f8171c |
| publicationDate |
2014-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014195280-A1 |
| titleOfInvention |
Immunogenic composition for use in therapy |
| abstract |
The application discloses a method of immunising against Staphylococcus aureus infection comprising a step of administering to a human patient a single dose of an immunogenic composition comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate, wherein the S. aureus Type 5 capsular saccharide conjugate is administered at a saccharide dose of 3- 50μg. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2015359503-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017079681-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11446371-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016091904-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2689161-C1 |
| priorityDate |
2013-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |